http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Orchard Therapeutics Outlines Comprehensive Presence at 2021 WORLDSymposium™
-
Orchard Therapeutics Outlines Comprehensive Presence at 2021 WORLDSymposium™
-
Orchard Therapeutics Secures Partnerships to Broaden Access to LibmeldyTM for Eligible Patients in Middle East & Turkey
-
Orchard Therapeutics Secures Partnerships to Broaden Access to LibmeldyTM for Eligible Patients in Middle East & Turkey
-
Orchard Therapeutics (ORTX) Announces OTL-200 Granted RMAT Designation by FDA for the Treatment of Metachromatic Leukodystrophy
-
Orchard Therapeutics Announces OTL-200 Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by FDA for the Treatment of Metachromatic Leukodystrophy (MLD)
-
Orchard Therapeutics Announces OTL-200 Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by FDA for the Treatment of Metachromatic Leukodystrophy (MLD)
-
Orchard Therapeutics (ORTX) Announces 2021 Corporate Priorities Supporting Build-out of its Commercial Business in Hematopoietic Stem Cell Gene Therapy and Expansion of its Clinical Applications
-
Orchard Therapeutics Announces 2021 Corporate Priorities Supporting the Build-out of its Commercial Business in Hematopoietic Stem Cell (HSC) Gene Therapy and Expansion of its Clinical Applications
-
Orchard Therapeutics Announces 2021 Corporate Priorities Supporting the Build-out of its Commercial Business in Hematopoietic Stem Cell (HSC) Gene Therapy and Expansion of its Clinical Applications
-
Orchard Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
-
Orchard Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
-
AGC Biologics Confirms Cell and Gene Therapy Commercial Expertise as Manufacturer of Orchard Therapeutics' Newly Approved Libmeldy™
-
Orchard Therapeutics Plc (ORTX) Receives EC Approval for Libmeldy for the Treatment of Early-Onset Metachromatic Leukodystrophy
-
Orchard Therapeutics Receives EC Approval for Libmeldy™ for the Treatment of Early-Onset Metachromatic Leukodystrophy (MLD)
-
Orchard Therapeutics Receives EC Approval for Libmeldy™ for the Treatment of Early-Onset Metachromatic Leukodystrophy (MLD)
-
Orchard Therapeutics Plc (ORTX) Announces OTL-201 Initial Clinical Data in Sanfilippo Syndrome Type A (MPS-IIIA)
-
Orchard Therapeutics (ORTX) Reports OTL-201 Initial Clinical Data in Sanfilippo Syndrome Type A
-
Orchard Therapeutics Reports OTL-201 Initial Clinical Data in Sanfilippo Syndrome Type A (MPS-IIIA)
-
Orchard Therapeutics Reports OTL-201 Initial Clinical Data in Sanfilippo Syndrome Type A (MPS-IIIA)
-
Rexgenero Appoints Sadia L’Baouch as Chief Manufacturing Officer
-
Orchard Therapeutics to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference
-
Orchard Therapeutics to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference
-
Orchard Therapeutics (ORTX) Announces FDA Clearance of IND Application for OTL-200 for MLD
-
Orchard Therapeutics Announces FDA Clearance of IND Application for OTL-200 for Metachromatic Leukodystrophy (MLD)
-
Orchard Therapeutics Announces FDA Clearance of IND Application for OTL-200 for Metachromatic Leukodystrophy (MLD)
-
Orchard Therapeutics Unveils Details on New HSC Gene Therapy Research Programs as Part of R&D Investor Event Tomorrow at 9:00 a.m. ET
-
Orchard Therapeutics Unveils Details on New HSC Gene Therapy Research Programs as Part of R&D Investor Event Tomorrow at 9:00 a.m. ET
-
Orchard Therapeutics to Present at Barclays Gene Editing & Gene Therapy Summit
-
Orchard Therapeutics to Present at Barclays Gene Editing & Gene Therapy Summit
-
Orchard Therapeutics Announces New OTL-201 Clinical Data in Sanfilippo Syndrome Type A (MPS-IIIA) Accepted for Oral Presentation at 62nd American Society of Hematology Annual Meeting
-
Orchard Therapeutics Announces New OTL-201 Clinical Data in Sanfilippo Syndrome Type A (MPS-IIIA) Accepted for Oral Presentation at 62nd American Society of Hematology Annual Meeting
-
Orchard Therapeutics Reviews Recent Portfolio Progress and Reports Third Quarter 2020 Financial Results
-
Orchard Therapeutics Reviews Recent Portfolio Progress and Reports Third Quarter 2020 Financial Results
-
Orchard Therapeutics to Host Virtual R&D Investor Event on Friday, November 13, 2020
-
Orchard Therapeutics to Host Virtual R&D Investor Event on Friday, November 13, 2020
-
Orchard Therapeutics CEO Bobby Gaspar, M.D., Ph.D., Appointed to the Alliance for Regenerative Medicine’s 2021 Board of Directors
-
Orchard Therapeutics CEO Bobby Gaspar, M.D., Ph.D., Appointed to the Alliance for Regenerative Medicine’s 2021 Board of Directors
-
Orchard Therapeutics Plc (ORTX) Reports Positive CHMP Opinion for Libmeldy
-
Orchard Therapeutics Receives Positive CHMP Opinion for Libmeldy™ for the Treatment of Early-Onset Metachromatic Leukodystrophy (MLD)
-
Orchard Therapeutics Receives Positive CHMP Opinion for Libmeldy™ for the Treatment of Early-Onset Metachromatic Leukodystrophy (MLD)
-
Orchard Therapeutics (ORTX) Receives EMA PRIME Designation for OTL-203 for the Treatment of MPS-I
-
Orchard Therapeutics Receives EMA PRIME Designation for OTL-203 for the Treatment of MPS-I
-
Orchard Therapeutics Receives EMA PRIME Designation for OTL-203 for the Treatment of MPS-I
-
Orchard Therapeutics to Present at Upcoming Virtual Investor Conferences
-
Orchard Therapeutics to Present at Upcoming Virtual Investor Conferences
-
Orchard Therapeutics Plc (ORTX) Highlights Additional Interim Results from Proof-of-Concept Study of OTL-203 for MPS-I
-
Orchard Therapeutics Announces Additional Interim Results from Proof-of-Concept Study of OTL-203 for MPS-I
-
Orchard Therapeutics Announces Additional Interim Results from Proof-of-Concept Study of OTL-203 for MPS-I
-
Orchard Therapeutics Announces Clinical Data Presentations at the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)
